Enlivex Therapeutics Ltd. (TLV: ENLV)

Market Cap	84.05M
Revenue (ttm)	n/a
Net Income (ttm)	-83.94M
Shares Out	n/a
EPS (ttm)	-4.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63,016
Open	451.90
Previous Close	451.90
Day's Range	426.00 - 451.90
52-Week Range	426.00 - 1,600.00
Beta	1.04
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Oren Hershkovitz
• Country: Israel
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: ENLV

Financial Performance

Financial numbers in USD